What is the role of mirabegron in the treatment of neurogenic bladder?

Updated: Dec 24, 2020
  • Author: Bradley C Gill, MD, MS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


Mirabegron was approved in 2012 by the US Food and Drug Administration (FDA) for the treatment of overactive bladder. In an initial study of its effectiveness for the treatment of neurogenic detrusor overactivity in 15 patients with spinal cord injury, a significant reduction of the frequency of bladder evacuation per 24 h (8.1 vs 6.4, P=0.003), and of incontinence episodes per 24 h (2.9 vs 1.3, P=0.027) was observed. However due to the limited size of the study, more research is needed. [21]

A systematic review of seven studies of mirabegron used as a treatment for neurogenic bladder concluded that it appeared to be an effective second-line treatment, particularly for patients with storage symptoms who were unresponsive to antimuscarinics . However, there was no evidence yet available to support its use as a first-line treatment. [22]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!